Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BarH-like homeobox 2 (BARHL2) is a sequence-specific DNA-binding transcription factor of the homeobox family that plays critical roles in neural development. It is expressed in developing neural tissues, especially the retina and spinal cord, where it promotes the differentiation of glycinergic amacrine cells while inhibiting bipolar and Müller glial cell formation during retinogenesis. In the spinal cord, BARHL2 regulates subtype diversification of interneurons, and its loss leads to fate changes in specific neuronal populations. BARHL2 also promotes neural progenitor survival, modulates cell cycle dynamics via caspase-3 and key signaling pathways, and is involved in diencephalon patterning through regulation of Sonic Hedgehog signaling. It is implicated as a biomarker in several cancers, notably oral squamous cell carcinoma and colorectal cancer, but is not currently pursued as a therapeutic target.
Not applicable; no drugs targeting BARHL2 are described
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BarH-like homeobox 2 (BARHL2).